The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice
De Caterina, R.
Italian Heart Journal. Supplement Official Journal of the Italian Federation of Cardiology 2(6): 681-684
2001
ISSN/ISBN: 1129-4728 PMID: 11460845 Document Number: 530271
Document emailed within 1 workday
Related Documents
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Nordt, T. 2001: Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project Der Internist 42(12): 1705-1707
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76
Engberg, M.; Christensen, B.; Karlsmose, B.; Lous, Jørgen.; Lauritzen, T. 2002: Can systematic general health screening and patient-physician health discussions improve the cardiovascular profile of the population? A randomized controlled trial in general practice with a 5-year follow-up Ugeskrift for Laeger 164(25): 3354-3360
Lala, A.; Berger, J.S. 2011: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding Evidence-Based Medicine 16(3): 80-81
Coutsoudis, A.; Pillay, K.; Spooner, E.; Kuhn, L.; Coovadia, H.M. 1999: Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African Vitamin A Study Group Aids 13(12): 1517-1524
May, T.; Beuscart, C.; Reynes, J.; Marchou, B.; Leclercq, P.; Borsa Lebas, F.; Saba, J.; Micoud, M.; Mouton, Y.; Canton, P. 1994: Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMi Study Group. Ligue Française de Prévention des Maladies Infectieuses Journal of Acquired Immune Deficiency Syndromes 7(5): 457-462
Lechat, P.; Lardoux, H.; Mallet, A.; Sanchez, P.; Derumeaux, G.; Lecompte, T.; Maillard, L.; Mas, J.L.; Mentré, F.; Pousset, F.; Lacomblez, L.; Pisica, G.; Solbes-Latourette, S.; Raynaud, P.; Chaumet-Riffaud, P. 2000: Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. a randomized trial (FFAACS) Therapie 55(6): 681-689
Gordin, F.; Chaisson, R.E.; Matts, J.P.; Miller, C.; de Lourdes Garcia, M.; Hafner, R.; Valdespino, J.L.; Coberly, J.; Schechter, M.; Klukowicz, A.J.; Barry, M.A.; O'Brien, R.J. 2000: Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group JAMA 283(11): 1445-1450
Miser, W.Fred. 2011: Appropriate aspirin use for primary prevention of cardiovascular disease American Family Physician 83(12): 1380-1386
Wawer, M.J.; Sewankambo, N.K.; Serwadda, D.; Quinn, T.C.; Paxton, L.A.; Kiwanuka, N.; Wabwire-Mangen, F.; Li, C.; Lutalo, T.; Nalugoda, F.; Gaydos, C.A.; Moulton, L.H.; Meehan, M.O.; Ahmed, S.; Gray, R.H. 1999: Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group Lancet 353(9152): 525-535
Soll, R.F.; Hoekstra, R.E.; Fangman, J.J.; Corbet, A.J.; Adams, J.M.; James, L.S.; Schulze, K.; Oh, W.; Roberts, J.D.; Dorst, J.P. 1990: Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group Pediatrics 85(6): 1092-1102
Uchiyama, S. 2010: Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients Rinsho Shinkeigaku 50(11): 832-834
Young, F.E.; Nightingale, S.L.; Temple, R.A. 1988: The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction JAMA 259(21): 3158-3160
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Ageno, W.; Crowther, M.; Steidl, L.; Ultori, C.; Mera, V.; Dentali, F.; Squizzato, A.; Marchesi, C.; Venco, A. 2002: Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial Thrombosis and Haemostasis 88(1): 48-51
Cohen, H. 1996: Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome Annales de Medecine Interne 147(Suppl): 44
Maciá Bobes, C.; Ronzón Fernández, Aánzazu.; Fernández García, E. 2007: Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA? Atencion Primaria 39(3): 163-164
Mutter, J.; Grandy, R.; Hulkower, S.; Stigleman, S. 2018: Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events? Journal of Family Practice 67(4): 247-248